9-ING-41 in Pediatric Patients With Refractory Malignancies.
Stopped The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.
Conditions
- Refractory Cancer
- Refractory Neoplasm
- Cancer Pediatric
- Refractory Tumor
- Pediatric Cancer
- Pediatric Brain Tumor
- Neuroblastoma
- Neuroblastoma Recurrent
- Pediatric Lymphoma
- Pediatric Meningioma
- Diffuse Intrinsic Pontine Glioma
Interventions
- DRUG: 9-ING-41
- DRUG: Irinotecan
- DRUG: Temozolomide
- DRUG: Cyclophosphamide
- DRUG: Topotecan
Sponsor
Actuate Therapeutics Inc.